LUCD and PAVMZ Related Headlines
Go Back- Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
- PAVmed Provides Business Update and Fourth Quarter and Full Year 2023 Financial Results
- Lucid Diagnostics Inc (LUCD) Provides Business Update, Reports Prelim Q4
- Lucid Diagnostics Provides Business Update and Preliminary Fourth Quarter and Full Year 2023 Financial Results
- Lucid Diagnostics Inc (LUCD) Announces Positive Data from the First Prospective Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population
- Lucid Diagnostics Announces Positive Data from the First Prospective Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population
- Lucid Diagnostics Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference
- Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 26, 2024
- Lucid Diagnostics Inc (LUCD) Provides Update Regarding World Trade Center Health Program
- Lucid Diagnostics Provides Update Regarding World Trade Center Health Program
- Lucid Diagnostics Chairman & CEO, Dr. Lishan Aklog, Highlights EsoCheck® Esophageal Cell Collection Device during Congressional Testimony
- Lucid Diagnostics Inc (LUCD) Executes Contract to Provide EsoGuard Esophageal Precancer Testing as a Covered Benefit for 9/11 Responders and Survivors
- Lucid Diagnostics Executes Contract to Provide EsoGuard® Esophageal Precancer Testing as a Covered Benefit for 9/11 Responders and Survivors
- Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Results from Three Clinical Utility Studies
- PAVmed Provides Additional Details for Upcoming Stock Dividend to Shareholders
- PAVmed (PAVM) Announces Dividend of Lucid Diagnostics (LUCD) Common Stock and Reverse Stock Split
- PAVmed Announces Dividend of Lucid Diagnostics Common Stock and Reverse Stock Split
- Lucid Diagnostics Inc (LUCD) Strengthens and Expands Market Access and Direct Contracting Efforts
- Lucid Diagnostics Strengthens and Expands Market Access and Direct Contracting Efforts
- PAVmed Provides Business Update and Third Quarter Financial Results
- Lucid Diagnostics Provides Business Update and Third Quarter Financial Results
- Lucid Diagnostics Launches Next-Generation EsoGuard® Esophageal DNA Test and Announces Upcoming Investor Day
- Lucid Diagnostics to Present at Canaccord Genuity Medtech, Diagnostics, and Digital Health & Services Forum
- PAVmed to Hold a Business Update Conference Call and Webcast on November 15, 2023
- Lucid Diagnostics Announces PREVENT and PREVENT-FF Registries of EsoGuard® Esophageal Precancer Detection
- Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 14, 2023
- PAVmed and Lucid Diagnostics to Participate in Panel Presentation at the 2023 Cantor Fitzgerald Global Healthcare Conference
- Lucid Diagnostics (LUCD) Releases Positive Data from First Prospective Clinical Utility Study of EsoGuard® Esophageal Precancer Detection
- Lucid Diagnostics Releases Positive Data from First Prospective Clinical Utility Study of EsoGuard® Esophageal Precancer Detection
- Lucid Diagnostics (LUCD) Releases Positive Data Demonstrating Clinical Utility of EsoGuard Esophageal Precancer Detection
- Lucid Diagnostics Releases Positive Data Demonstrating Clinical Utility of EsoGuard® Esophageal Precancer Detection in Fire Fighters
- Lucid Diagnostics Executes First Direct Employer Contract to Provide EsoGuard® Esophageal Precancer Testing as an Employee Benefit
- PAVmed (PAVM) Reports Q2, Provides Business Update
- PAVmed Provides Business Update and Second Quarter Financial Results
- Lucid Diagnostics Provides Business Update and Second Quarter Financial Results
- PAVmed to Hold a Business Update Conference Call and Webcast on August 16, 2023
- Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 15, 2023
- Lucid Diagnostics to Present at the Canaccord Genuity 43rd Annual Growth Conference
- PAVmed and Lucid Chairman and Chief Executive Officer, Dr. Lishan Aklog, Testifies at U.S. House of Representatives Energy and Commerce Committee, Hearing on Life-Saving Innovations and Medicare Cover
- PAVmed (PAVM) Granted 180-Day Extension to Regain Nasdaq Compliance
- PAVmed Receives 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement
- PAVmed to Participate in Healthcare Virtual Conference Presented by Maxim Group LLC
- Lucid Diagnostics Launches First EsoGuard® Mobile Test Unit
- PAVmed Digital Health Subsidiary, Veris Health, Joins Cancer Moonshot's CancerX Partnership as Founding Member
- PAVmed Provides Business Update and First Quarter Financial Results
- Lucid Diagnostics Inc (LUCD) Reports Q1, Provides Business Update
- Lucid Diagnostics Provides Business Update and First Quarter Financial Results
- Lucid Diagnostics and Collaborators Present New EsoGuard® and EsoCheck® Data at Digestive Disease Week® (DDW) 2023 Conference
- Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 16, 2023
- PAVmed to Hold a Business Update Conference Call and Webcast on May 17, 2023
- PAVmed Digital Health Subsidiary, Veris Health, Appoints Gary Manning as President
- PAVmed Digital Health Subsidiary, Veris Health, to Present Comprehensive Meta-analysis on Impact of Remote Patient Monitoring in Oncology at HIMSS
LUCD and PAVMZ Related Press Releases
Go Back- Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
- PAVmed Provides Business Update and Fourth Quarter and Full Year 2023 Financial Results
- Lucid Diagnostics Provides Business Update and Preliminary Fourth Quarter and Full Year 2023 Financial Results
- Lucid Diagnostics Announces Positive Data from the First Prospective Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population
- Lucid Diagnostics Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference
- Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 26, 2024
- Lucid Diagnostics Provides Update Regarding World Trade Center Health Program
- Lucid Diagnostics Chairman & CEO, Dr. Lishan Aklog, Highlights EsoCheck® Esophageal Cell Collection Device during Congressional Testimony
- Lucid Diagnostics Executes Contract to Provide EsoGuard® Esophageal Precancer Testing as a Covered Benefit for 9/11 Responders and Survivors
- Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Results from Three Clinical Utility Studies
- PAVmed Provides Additional Details for Upcoming Stock Dividend to Shareholders
- PAVmed Announces Dividend of Lucid Diagnostics Common Stock and Reverse Stock Split
- Lucid Diagnostics Strengthens and Expands Market Access and Direct Contracting Efforts
- PAVmed Provides Business Update and Third Quarter Financial Results
- Lucid Diagnostics Provides Business Update and Third Quarter Financial Results
- Lucid Diagnostics Launches Next-Generation EsoGuard® Esophageal DNA Test and Announces Upcoming Investor Day
- Lucid Diagnostics to Present at Canaccord Genuity Medtech, Diagnostics, and Digital Health & Services Forum
- PAVmed to Hold a Business Update Conference Call and Webcast on November 15, 2023
- Lucid Diagnostics Announces PREVENT and PREVENT-FF Registries of EsoGuard® Esophageal Precancer Detection
- Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 14, 2023
- PAVmed and Lucid Diagnostics to Participate in Panel Presentation at the 2023 Cantor Fitzgerald Global Healthcare Conference
- Lucid Diagnostics Releases Positive Data from First Prospective Clinical Utility Study of EsoGuard® Esophageal Precancer Detection
- Lucid Diagnostics Releases Positive Data Demonstrating Clinical Utility of EsoGuard® Esophageal Precancer Detection in Fire Fighters
- Lucid Diagnostics Executes First Direct Employer Contract to Provide EsoGuard® Esophageal Precancer Testing as an Employee Benefit
- PAVmed Provides Business Update and Second Quarter Financial Results
- Lucid Diagnostics Provides Business Update and Second Quarter Financial Results
- PAVmed to Hold a Business Update Conference Call and Webcast on August 16, 2023
- Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 15, 2023
- Lucid Diagnostics to Present at the Canaccord Genuity 43rd Annual Growth Conference
- PAVmed and Lucid Chairman and Chief Executive Officer, Dr. Lishan Aklog, Testifies at U.S. House of Representatives Energy and Commerce Committee, Hearing on Life-Saving Innovations and Medicare Cover
- PAVmed Receives 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement
- PAVmed to Participate in Healthcare Virtual Conference Presented by Maxim Group LLC
- Lucid Diagnostics Launches First EsoGuard® Mobile Test Unit
- PAVmed Digital Health Subsidiary, Veris Health, Joins Cancer Moonshot's CancerX Partnership as Founding Member
- PAVmed Provides Business Update and First Quarter Financial Results
- Lucid Diagnostics Provides Business Update and First Quarter Financial Results
- Lucid Diagnostics and Collaborators Present New EsoGuard® and EsoCheck® Data at Digestive Disease Week® (DDW) 2023 Conference
- Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 16, 2023
- PAVmed to Hold a Business Update Conference Call and Webcast on May 17, 2023
- PAVmed Digital Health Subsidiary, Veris Health, Appoints Gary Manning as President
- PAVmed Digital Health Subsidiary, Veris Health, to Present Comprehensive Meta-analysis on Impact of Remote Patient Monitoring in Oncology at HIMSS
